181 related articles for article (PubMed ID: 21352561)
21. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
Hainsworth JD; Greco FA; Raefsky EL; Thompson DS; Lunin S; Reeves J; White L; Quinn R; DeBusk LM; Flinn IW
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):277-83. PubMed ID: 24679633
[TBL] [Abstract][Full Text] [Related]
22. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy.
Bains P; Al Tourah A; Campbell BA; Pickles T; Gascoyne RD; Connors JM; Savage KJ
Ann Oncol; 2013 Feb; 24(2):428-432. PubMed ID: 23035152
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
[TBL] [Abstract][Full Text] [Related]
24. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal?
Mondello P; Steiner N; Wasle I; Pitini V; Mian M
Anticancer Res; 2014 Nov; 34(11):6701-4. PubMed ID: 25368277
[TBL] [Abstract][Full Text] [Related]
26. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Leuk Lymphoma; 2015; 56(8):2350-6. PubMed ID: 25426666
[TBL] [Abstract][Full Text] [Related]
27. Rituximab maintenance therapy for follicular lymphoma: no better than watchful waiting.
Prescrire Int; 2012 Mar; 21(125):62. PubMed ID: 22428182
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.
Friedberg JW; Byrtek M; Link BK; Flowers C; Taylor M; Hainsworth J; Cerhan JR; Zelenetz AD; Hirata J; Miller TP
J Clin Oncol; 2012 Sep; 30(27):3368-75. PubMed ID: 22915662
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
Persky DO; Unger JM; Spier CM; Stea B; LeBlanc M; McCarty MJ; Rimsza LM; Fisher RI; Miller TP;
J Clin Oncol; 2008 May; 26(14):2258-63. PubMed ID: 18413640
[TBL] [Abstract][Full Text] [Related]
30. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
[TBL] [Abstract][Full Text] [Related]
31. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Persky DO; Dornan D; Goldman BH; Braziel RM; Fisher RI; Leblanc M; Maloney DG; Press OW; Miller TP; Rimsza LM
Haematologica; 2012 Jun; 97(6):937-42. PubMed ID: 22271896
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Davies A; Merli F; Mihaljevic B; Siritanaratkul N; Solal-Céligny P; Barrett M; Berge C; Bittner B; Boehnke A; McIntyre C; Macdonald D
Lancet Oncol; 2014 Mar; 15(3):343-52. PubMed ID: 24521993
[TBL] [Abstract][Full Text] [Related]
34. Rituximab maintenance versus retreatment in follicular lymphoma.
Palla AR; Hamadani M
Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794
[TBL] [Abstract][Full Text] [Related]
35. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
[TBL] [Abstract][Full Text] [Related]
36. Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients.
Heinzelmann F; Ottinger H; Engelhard M; Soekler M; Bamberg M; Weinmann M
Strahlenther Onkol; 2010 May; 186(5):247-54. PubMed ID: 20437015
[TBL] [Abstract][Full Text] [Related]
37. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.
Jurczak W; Moreira I; Kanakasetty GB; Munhoz E; Echeveste MA; Giri P; Castro N; Pereira J; Akria L; Alexeev S; Osmanov E; Zhu P; Alexandrova S; Zubel A; Harlin O; Amersdorffer J
Lancet Haematol; 2017 Aug; 4(8):e350-e361. PubMed ID: 28712941
[TBL] [Abstract][Full Text] [Related]
38. Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.
MacManus M; Fisher R; Roos D; O'Brien P; Macann A; Davis S; Tsang R; Christie D; McClure B; Joseph D; Jayamohan J; Seymour JF
J Clin Oncol; 2018 Oct; 36(29):2918-2925. PubMed ID: 29975623
[TBL] [Abstract][Full Text] [Related]
39. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Jäger U; Fridrik M; Zeitlinger M; Heintel D; Hopfinger G; Burgstaller S; Mannhalter C; Oberaigner W; Porpaczy E; Skrabs C; Einberger C; Drach J; Raderer M; Gaiger A; Putman M; Greil R;
Haematologica; 2012 Sep; 97(9):1431-8. PubMed ID: 22511498
[TBL] [Abstract][Full Text] [Related]
40. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
